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Background: Dementia imposes a heavy burden on health and social care systems as well as on family caregivers
who provide a substantial portion of the care. Interventions that effectively support caregivers may prevent or delay
patient institutionalization and hence be cost-effective. However, evidence about the cost-effectiveness of such
interventions is scarce. The aim of this study was to evaluate the cost-effectiveness of a family meetings
intervention for family caregivers of dementia patients in comparison with usual care over a period of 12 months.
Methods: The economic evaluation was conducted from a societal perspective alongside a randomized trial of 192
primary caregivers with community-dwelling dementia patients. Outcome measures included the Quality Adjusted
Life-Years (QALY) of caregivers and patients and the incidence of depression and anxiety disorders in caregivers.
Missing cost and effect data were imputed using multiple imputations. Bootstrapping was used to estimate
uncertainty around the cost-differences and the incremental cost-effectiveness ratio (ICER). The bootstrapped
cost-effect pairs were plotted on a cost-effectiveness plane and used to estimate cost-effectiveness curves.
Results: No significant differences in costs and effects between the groups were found. At 12 months, total costs
per patient and primary caregiver dyad were substantial: €77,832 for the intervention group and €75,201 for the
usual care group (adjusted mean difference per dyad €4,149, 95% CI −13,371 to 21,956, ICER 157,534). The main
cost driver was informal care (66% of total costs), followed by patients’ day treatment and costs of hospital and
long-term care facility admissions (23%). Based on the cost-effectiveness acceptability curves, the maximum
probability that the intervention was considered cost-effective in comparison with usual care reached 0.4 for the
outcome QALY per patient-caregiver dyad and 0.6 for the caregivers’ incidence of depression and/or anxiety
disorders regardless of the willingness to pay.
Conclusions: The annual costs of caring for a person with dementia were substantial with informal care being by
far the largest contributor to the total societal costs. Based on this study, family meetings cannot be considered a
cost-effective intervention strategy in comparison with usual care.
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Dementia is a common and disabling disorder in elderly
people and the number of people affected is expected to
rise exponentially [1]. The majority of people with de-
mentia live in the community where informal caregivers
are the main providers of care. Providing care for a rela-
tive with dementia can be stressful and demanding, lead-
ing to a high burden and significant physical and mental
health problems [2-7] compared to non-caregivers [8].
The worldwide costs of dementia (US$604 billion in 2010)
already amount to more than 1% of the global gross do-
mestic product [9]. Further, dementia patients have in-
creased healthcare utilization rates compared with other
major diseases [10-12]. Previous research showed that in-
formal care costs make up a substantial part of the total
annual costs of dementia. In the United States, the care
provided by informal caregivers to people with dementia
was valued at more than $202 billion in 2010 [13]. Also, in
the United Kingdom and Scandinavia, informal care ac-
count for a substantial proportion (55% and 33%, respec-
tively) of the annual cost of dementia [14,15]. In several
countries, the current health care workforce may not be
numerous enough to meet the care needs of the increas-
ing number of older patients; this might place even more
pressure on family and other informal caregivers in the
near future [16-19].
Dementia thus imposes a heavy economic burden on
the social care system, as well as on family and friends
who provide unpaid care. Interventions which effectively
support caregivers and prevent psychiatric morbidity may
postpone institutionalization of the patient with dementia
[20,21], decrease work absenteeism and healthcare utiliza-
tion of the caregiver and may hence be cost-effective in
comparison with usual care. Information about the trade-
off between costs and benefits of caregiver interventions
is urgently needed since it will enable policy makers to
understand the magnitude of the economic consequences
and to decide whether it is efficient to implement such in-
terventions considering the scarce resources available for
healthcare. A large number of studies evaluated the effec-
tiveness of supportive interventions for informal caregi-
vers of people with dementia [22-24], but recent reviews
showed that there are only few economic evaluations of
such interventions. Moreover, the available studies in this
field often have insufficient methodological quality and
measured costs from a narrow perspective [25,26]. Some
studies analysed effect and cost differences between groups
separately instead of comparing the total cost of each op-
tion against the total effects. Furthermore, often not all
relevant cost categories such as informal care costs and lost
productivity costs were taken into consideration, and hence,
these studies were not performed from a societal perspec-
tive. The systematic review of Jones et al. [25] on the cost-
effectiveness of interventions targeted at informal dementiacaregivers identified only four psychosocial interventions
and four other types of non-pharmacological interventions
that were evaluated in studies with sufficient quality [25].
Only one of these psychosocial interventions reported to be
cost-effective compared with usual care [27].
A psychosocial intervention targeted at the whole fam-
ily, such as family meetings, may be a potentially cost-
effective approach. Family meetings may maximize the
positive contribution of family members, decrease care-
giver burden, alleviate psychological symptoms [28,29]
or even prevent the primary caregiver from developing a
psychiatric disorder, such as a depressive or anxiety dis-
order. This might enable the caregiver to provide care for a
longer time, thereby leading to decreased healthcare
utilization and loss of productivity and postponement of
patient institutionalization. Previously, a multi-component
intervention program for caregivers that consisted of four
family meetings, two individual counselling sessions with
the caregiver, support group participation and ad hoc coun-
selling was shown to decrease depressive symptoms in in-
formal caregivers and to result in a substantial delay in time
until nursing home placement of patients [20,21,28-30].
Joling et al. subsequently investigated, in a pragmatic trial,
whether a structured family meetings intervention could
prevent mental disorders and reduce the severity of symp-
toms in caregivers of persons with dementia thus delaying
institutionalization of patients. Clinically, the effects were
smaller than anticipated. Although the incidence of depres-
sion and anxiety disorders was substantial in the sample
of caregivers, the intervention did not prevent the onset
of disorders, nor reduce symptom levels or delayed time
until institutionalization of patients compared to usual care
[31-33]. Evidence on the cost-effectiveness of family meet-
ings is still lacking; little is known about the costs associated
with such interventions and the relationship between costs
and effects. This article presents the first cost-effectiveness
analysis alongside a randomized trial of a family meeting
intervention for caregivers of patients with dementia in
comparison with usual care.
Methods
Study design, setting and participants
The economic evaluation was performed alongside a ran-
domized trial to evaluate a family meetings intervention in
comparison with usual care from a societal perspective.
The follow-up of the study was 12 months. Caregiver and
patient dyads were recruited through memory clinics (n =
91), organizations delivering case management (n = 79),
general practices, home care settings and meeting centres
for people with dementia and their caregivers (n = 22) in
the Netherlands. Caregivers were eligible if they were the
primary family caregiver of a community-dwelling relative
with a clinical diagnosis of dementia and had at least one
other family member or friend available to participate in
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caregiver caring for the patient, the primary caregiver was
defined as the person who coordinated the caring process,
usually the person who spent most hours on caregiving
tasks. Caregivers were excluded when 1) they met the
criteria for a clinical depressive or anxiety disorder as
measured with the Mini International Neuropsychiatric
Interview (MINI) [34], 2) their relative with dementia was
scheduled to move into a nursing home, 3) they presented
with severe somatic or psychiatric co-morbidity which
would significantly impair cooperation with the study.
Persons who gave written informed consent and had suffi-
cient command of the Dutch language were eligible for
participation in the study; the design of the study has been
described in detail elsewhere [31]. The Medical Ethics
Committee of the VU University Medical Centre approved
the study protocol.
Randomization and blinding
After obtaining signed informed consent and baseline
measurements, dyads of patients and their primary fam-
ily caregiver were randomized by an independent re-
searcher stratified by recruitment centre in blocks of
four to either usual care or the family meetings interven-
tion. The interviewers who measured the outcomes were
blinded to randomization status. Blinding of participants
and the counsellors conducting the family meetings was
not possible due to the nature of the intervention.
Intervention
The family meetings intervention has been described in
detail elsewhere [31,32]. Briefly, caregivers randomized to
the intervention group were invited to participate in six
in-person counselling sessions: one individual preparation
session, followed by four structured meetings that included
their relatives and/or friends (family meetings), and one
additional individual evaluation session. The family meet-
ings were held once every 2 to 3 months in the year fol-
lowing enrolment in the program. The aim of the family
meetings was to offer psycho-education, teach problem-
solving techniques and mobilize the existing family net-
works of the patient and primary caregiver in order to
improve emotional and instrumental support. The content
of the sessions was guided by the needs of the caregiver.
The intervention protocol recommended that patients
would not attend the family meetings, unless the caregiver
strongly desired the patient to be present. Ad hoc tele-
phone counselling from the same counsellor was available
to caregivers and their families beyond the scheduled ses-
sions. The counsellors who led the family meetings had an
advanced degree in nursing, social work, psychology or an
allied profession and were trained prior to the study by the
research team. The total estimated time for the interven-
tion was 6.5 hours per patient-caregiver dyad, includingthe time spent for the individual and family sessions (5.5
hours) and administration and preparation time for the
counsellor (1 hour). Intervention participants also had ac-
cess to all the usual types of care.
Usual care
Participants randomized to the usual care group were free
to use all types of care, including community-based mental
health services or support resources other than family
meetings at any time throughout the 12 months follow-up,
reflecting standard care. Usual care in the Netherlands
may consist of a range of health and social care services
and can differ across participants. However, family meet-
ings are rarely organized or offered in a structured way
with follow-up sessions. They also tend to focus on provid-
ing clinical information and not on increasing family sup-
port and relieving the caregiver.
Effect outcomes
Effect outcomes were the quality of life of the patient and
caregiver (as a dyad and separately) and the incidence of
major depressive or anxiety disorders in caregivers. Quality-
of-life of caregivers and patients was measured using the
SF-12 at baseline and at 6 and 12 months [35]; the caregiver
rated the patient’s quality of life. The tariff developed by
Brazier et al. [36] was used to convert health states to util-
ities [36]. Utilities express the relative desirability of a health
state on a scale of 0 (‘death’) to 1 (‘perfect health’). QALYs
were calculated by multiplying the utilities with the amount
of time a person spent in a particular health state. Transi-
tions between health states were linearly interpolated.
The incidence of depression and anxiety was measured
at baseline and at 3, 6, 9 and 12 months after enrolment
with the MINI [34], a short diagnostic interview for
DSM-IV mental disorders that can be used for psychi-
atric evaluation and outcome tracking.
Cost outcomes
Cost data were collected from a societal perspective
using two consecutive cost diaries that covered a period
of 6 months each as well as 6-monthly interview assess-
ments to measure informal care time; direct and indirect
costs of both the caregiver and patient were gathered.
Table 1 lists the cost categories and prices used in this
economic evaluation. All costs were adjusted to the year
2009 using consumer price indices if necessary. The year
2009 was chosen because most cost data were collected
during that year. Costs were calculated by multiplying
the units of resource use by their cost price according to
the Dutch guidelines for health economic evaluations
[37]. If no standard cost was available, tariffs were used.
Medication costs were valued using prices of the Royal
Dutch Society for Pharmacy [38]. Lost productivity costs
were calculated according to the friction cost approach
Table 1 Prices used in the economic evaluation and utilization of health care resources and work absenteeism for
caregivers and patients with complete cost data during the 12-month follow-up period
Cost category Unit Unit cost Caregivers Patients
(€, 2009) (n = 125) (n = 118)
Mean (SD) Mean (SD)
Ambulatory care (except home care)
General practitioner Contact 28a 5.0 (4.3) 4.9 (5.4)
Paramedical therapist Contact Variableb 7.3 (14.3) 10.2 (19.9)
Psychologist or psychotherapist Contact 80 or 77 0.5 (2.7) 0.2 (0.7)
Social worker Contact 65 0.2 (1.0) 0.4 (2.0)
Social psychiatric nurse Contact 45 1.7 (3.3) 1.8 (3.6)
Psychiatrist Contact 171 0.03 (0.4) 0.2 (0.7)
Other counsellorc Contact Variable 0.3 (1.5) n/a
Peer support group counselling Session 68 1.8 (3.8) 0.1 (0.7)
Outpatient appointment Contact 72 2.6 (3.0) 3.9 (3.8)
Home care and other support
Domestic home help Hour 24 10.6 (17.5) see caregiver
Professional home care Hour 44 0.5 (4.2) 5.4 (15.8)
Respite care Hour 12.50 1.6 (8.3) n/a
Meal supply at home Meal 6 2.7 (20.6) 3.4 (22.8)
Day treatment and admissions
Day treatment Day 251 1.6 (8.2) 48.3 (67.2)
Admission, elderly home Day 90 0.2 (2.3) 1.1 (7.6)
Admission, nursing home Day 238 0.4 (3.8) 15.2 (46.1)
Admission, academic hospital Day 575 0.2 (2.0) 0.3 (1.8)
Admission, non-academic hospital Day 435 0.4 (1.9) 1.0 (5.5)
Admission, intensive care unit Day 2183 0.02 (0.2) none
Absenteeism
Paid labour Day Friction costsd 2.2 (11.7) n/a
Unpaid labour Hour 12.50 4.7 (20.7) n/a
Informal care Hour 12.50 see patient 3760.3 (3273.0)
aPrices of GP telephone contacts and GP home visits involved €14 and €43, respectively.
bParamedical therapists included: physiotherapist, manual therapist, Cesar exercise therapists, alternative therapists. For each profession, the appropriate guideline
price was used and if not available, the mean of the price according to five therapists was used.
cOther counsellors included counselling sessions with a caregiver consultant, a coordinator of meeting centres for persons with dementia and their caregivers or a
practice nurse. Prices were according to the professional organization.
dCosts for paid labour were calculated on the basis of a mean income of the Dutch population according to age and sex.
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specific income of the Dutch population [39,40]. The
intervention costs were calculated based on the time in-
vestment of the counsellors including 15 minutes of ad-
ministration by the counsellors per family session and
the time spent by the counsellors on the individual and
family counselling sessions (€45.35 per hour). Travel costs
and capital costs were not included. Informal caregiver time
was valued using a shadow price based on the hourly cost
of a legally employed cleaning person (€12.50 per hour) as
recommended in the Dutch guidelines. Caregivers were
asked how much time they spent on a list of informal care
tasks during the previous day. Informal care tasks included:
support with activities of daily living (ADL), support withinstrumental activities of daily living (IADL), household ac-
tivities of daily living (HDL) and supervision tasks. The
total informal care time was calculated by adding up the
reported time on these tasks during the previous day, using
a maximum of 24 hours. We extrapolated the time per day
reported at baseline, 6 and 12 months to determine the
total amount of carer time during 12 months of follow-up.
Power calculation
The power calculation was based on the expected effects
of the intervention on the main outcome measure, inci-
dence of a depression or anxiety disorder. The yearly inci-
dence of disorders among caregivers at risk was estimated
at 30% [3]. The trial was powered to detect a 20% decrease
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group would be needed, assuming a 2-sided test, an alpha
of 0.05 and a power of 80%. With a dropout of 20%, at
least 182 participants were needed.
Statistical analysis
The economic evaluation included a cost-utility analysis
with the QALY as the effect (analysed for the patient-
caregiver dyad as well as for caregivers and patients QALYs
separately) and a cost-effectiveness analysis with the care-
giver’s incident depression and/or anxiety disorder as the
effect. The statistical analyses were performed according to
the intention-to-treat principle (ITT). Multiple imputation
was used to impute missing cost and effect data. Variables
found to be related to cost and effect outcomes and missing
follow-up data, were included in the multiple imputation
model. Each of the 10 imputed data sets were separately
analysed and the results of the 10 analyses were pooled
using Rubin’s rules [41]. To adjust for selection bias, vari-
ables with significant baseline differences between the in-
tervention and usual care group (caregiver anxiety score
(HADS-A) [42], age of the patient and age of the caregiver)
were incorporated as covariates in the analyses. For costs,
linear regression models were estimated. Costs generally
have a highly skewed distribution; therefore, bootstrapping
with 5,000 replications was used to estimate bias-corrected
and accelerated confidence intervals around cost differ-
ences [43,44]. Cost-effectiveness was expressed as an incre-
mental cost effectiveness ratio (ICER) for the intervention
compared to the control condition, a measure of the add-
itional cost per unit of health gain. ICERs were calculated
by dividing the difference in total costs between the inter-
vention and usual care group by the difference in clinical
effects. A bivariate regression model was estimated with
separate regression equations for costs and effects includ-
ing covariates. Non-parametric bootstrapping was also used
to estimate the uncertainty surrounding the incremental
cost-effectiveness and cost-utility ratios (5,000 replications).
The bootstrapped cost-effect pairs were plotted on a cost-
effectiveness plane and used to estimate cost-effectiveness
acceptability (CEA) curves. In a cost-effectiveness plane, in-
cremental costs between the intervention and usual care
are plotted on the y-axis and incremental effects on the x-
axis resulting in four quadrants. The northeast quadrant in-
dicates that the intervention is more expensive and more
effective than usual care. In the southeast quadrant the in-
tervention dominates usual care, i.e. is less expensive and
more effective than usual care. In the southwest quadrant
the intervention is less expensive and less effective than
usual care. Finally, in the northwest quadrant the interven-
tion is dominated by usual care (more expensive and less
effective). Most newly developed interventions are more ex-
pensive and more effective than usual care, which implies
that a trade-off needs to be made about whether theadditional benefits justify the additional costs. This decision
depends on the societal willingness to pay for an additional
unit of effect. However, this willingness to pay is generally
not known. CEA curves show the probability that the inter-
vention is cost-effective in comparison with the control
treatment for a range of willingness to pay values [45]. Fi-
nally, two sensitivity analyses were carried out. Complete
case analyses were performed using only persons with
complete follow-up cost and effect data to assess whether
missing data might have caused bias. Furthermore, the ITT
analyses were repeated without adjustment to assess the
impact of the baseline imbalances and to check the robust-
ness of the results.
Results
Participant flow and recruitment
Participants were recruited from November 2007 to
November 2009. Figure 1 presents the flow chart of the
study sample. Of the caregivers assessed for eligibility,
192 met all inclusion criteria and were willing to par-
ticipate. Reasons for exclusion included not meeting the
inclusion criteria (n = 81) and refusal of participation (n =
410) and were described in detail elsewhere [32]. Summa-
rized, the primary reason for refusal was a claimed lack
of need for this intervention. There were no significant
differences between the patient-caregiver dyads that re-
fused participation and the participating dyads in gender,
caregiver-patient relation and the type of service they were
recruited from.
Baseline characteristics
Table 2 presents the socio-demographic and clinical charac-
teristics of the caregivers and patients at baseline. Patients
and caregivers in the intervention group were significantly
younger (patient’s age: t = 3.07, degrees of freedom (df) =
188.10, 95% CI for difference in means: 1.37 to 6.33, and
caregivers’ age: t = 2.27, df = 188.47, 95% CI: 0.45 to 6.30)
and caregivers in the intervention group had higher levels
of anxious symptoms (HADS-A score) (t = −2.51, df = 187,
95% CI for difference in means: −2.22 to −0.27) at baseline
than participants in the usual care group.
Numbers analysed
Complete follow-up data (cost data and both the QALY
and MINI effect outcome data) were available for 44 (46%)
intervention and 57 (59%) usual care group caregivers. For
patients, complete follow-up data were available for 48 pa-
tients (50%) in the intervention group and 54 patients
(56%) in the usual care group. Missing follow-up data was
significantly associated with the number of ADL depend-
encies (mean difference 0.44, 95% CI 0.09 to 0.79), the
number of IADL dependencies (mean difference 0.75, 95%
CI 0.29 to 1.21) and lower mini mental state examination
scores (mean difference −1.92, 95% CI −3.46 to −0.37) of
Randomized (n=192)
Assessed for eligibility (n=683)
Lost to follow up (n=10)
6 too burdensome
4 not useful
Complete cost and primary outcome data 
during 12 month follow-up for patients and 
caregivers (n=48)
Allocated to usual care (n=96)Allocated to intervention (n=96)
received allocated intervention (n=91)
did not receive allocated intervention (n=5)
1 distance too large
1 patient died
2 too stressful / burdensome
1 not useful
Excluded (n=491)
not meeting inclusion criteria (n=81)
refused to participate (n=410)
Intention to treat analyses (n=96)
Complete case analysis
- Outcome QALY dyad (n=48)
- Outcome QALY caregiver (n=55)
- Outcome QALY patient (n=48)
- Outcome MINI caregiver (n=47)
Intention to treat analyses (n=96)
Complete case analysis
- Outcome QALY dyad (n=53)
- Outcome QALY caregiver (n=64)
- Outcome QALY patient (n=54)
- Outcome MINI caregiver (n=59)
Completed intervention (n=44)





Complete cost and primary outcome data 
during 12 month follow-up for patients and 
caregivers (n=39)
Figure 1 Flow chart of the study sample.
Table 2 Baseline demographic and clinical characteristics of the caregivers and patients
Caregiver Patient
Intervention (n = 96) Usual care (n = 96) Intervention (n = 96) Usual care (n = 96)
Age, M (SD) 67.8 (9.8)* 71.2 (10.7) 72.8 (9.1)* 76.7 (8.3)
Female gender, n (%) 67 (69.8) 68 (70.8) 30 (31.3) 32 (33.3)
Spouse of the patient, n (%) 92 (95.8) 89 (92.7)
Living with patient, n (%) 93 (96.9) 91 (94.8)
Educational level, n (%)
Elementary/Lower 28 (29.2) 34 (35.4) 42 (43.8) 44 (45.8)
Secondary 37 (38.5) 30 (31.3) 30 (31.3) 28 (29.2)
Higher/ University 29 (30.2) 32 (33.3) 24 (25.0) 22 (22.9)
Utility score SF6D, M (SD) 0.8 (0.01) 0.7 (0.01) 0.7 (0.01) 0.7 (0.01)
Anxiety score HADS-A (0–21), M (SD) 6.1 (3.4)* 4.8 (3.5)
Depression score CES-D (0–60), M (SD) 12.1 (7.9) 10.8 (7.1)
ADL independencies (out of 6), M (SD) 5.1 (1.4) 5.3 (1.1)
IADL independencies (out of 7), M (SD) 2.7 (1.8) 2.6 (1.5)
MMSE (0–30), M (SD) 21.4 (4.9) 21.7 (5.6)
M: Mean; SD: Standard deviation; HADS-A: Hospital Anxiety and Depression Scales- Anxiety subscale; CES-D: Centre for Epidemiologic Studies Depression Scale;
(I) ADL: (Instrumental) activities of daily living; MMSE: Mini Mental State Examination.
*significant difference with usual care group (P <0.05).
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missing follow-up data were imputed and all participants
were included in the analyses.
Uptake of the intervention
Of those randomized to the intervention group, 91/96
participated in the preparation session, 73/96 attended 1
or 2 family meetings and 44/96 adhered (i.e., completed
the preparation session plus 3 or 4 family meetings within
12 months) to the intervention protocol.
Costs
Table 3 presents the mean costs and adjusted differences
in costs for caregivers and patients between the inter-
vention and usual care group. Ambulatory care costs in
the intervention group were significantly lower. Further,
considerable investments need to be done to provide the
intervention in addition to usual care. Total costs were
€77,832 per patient-caregiver dyad in the intervention
group and €75,201 in the usual care group (mean ad-
justed difference €4,149, 95% CI −13371; 21956). Patient
costs were the majority of the total costs (€73,854 in the
intervention group and €70,684 in the control group per
patient) and only a relatively small amount concerned
costs for caregivers (€3,979 in the intervention group
and €4,517 in the control group per caregiver). Although
statistically non-significant, costs for caregivers were in
favour of the intervention group (mean adjusted differ-
ence €788, 95% CI −3529; 1439), while for patients costsTable 3 Unadjusted and adjusted differences in costs (€) for c
Cost category Intervention (n = 96) Usual care (n
M (SD) M
Caregiver
Ambulatory care 842 (103) 1,110
Day treatment and admissions 854 (454) 1,074
Home care and other support 751 (171) 1,253
Absenteeism 1,133 (640) 691
Medication 271 (48) 38
Intervention 129 (10)
Total caregiver 3,979 (884) 4,517
Patient
Ambulatory care 1,057 (115) 1,016
Day treatment and admissions 18,388 (2639) 17,124
Home care and other support 1,451 (425) 1,581
Medication 1,097 (131) 1,106
Informal care 51,860 (4585) 49,858
Total patient 73,854 (6106) 70,684
Total patient- caregiver dyad 77,832 (6384) 75,201
*95% CI obtained by bias corrected and accelerated bootstrapping.
**Cost differences adjusted for variables that differed significantly between intervention a
***Indicates a statistically significant difference between the intervention and usualwere lower in the usual care group (mean adjusted differ-
ence €4,936, 95% CI −11808; 21750), which was mainly
due to lower informal care costs. Informal care costs were
by far the largest contributor to total dyadic costs (66%)
with an average amount of €50,859. This means that care-
givers spent on average 11 hours per day on caregiving, in-
cluding supervision. Another large cost driver involved
day treatment and admissions of the patient to hospitals
and long-term care facilities which amounted to an aver-
age of €17,756 per patient. The volumes of resource use
for patients and caregivers with complete cost data are
shown in Table 1.
Effects
Full details on the clinical outcomes were presented in
the accompanying clinical paper [32,33]. Briefly, a substan-
tial number (37/96; 39.6%) of caregivers in the intervention
group and in the usual care group (34/96; 35.4%) developed
a depressive or anxiety disorder within 12 months. The in-
cidence was similar in both groups (adjusted difference
0.01; 95% CI −0.14 to 0.17, Table 4). There was no statisti-
cally significant difference in quality of life for either the pa-
tients, caregivers or patient-caregiver dyads (Table 4).
Cost-effectiveness
Since the differences in effects on all outcomes were
very small, this resulted in very large ICERs that will be
very sensitive to uncertainty in incremental effect (Table 4).







(124) −268 −571; 20 −335 −663; -28***
(436) −220 −1371; 1081 −107 −1327; 1272
(247) −502 −1151; 7 −438 −1015; 57
(458) 442 −742; 2058 57 −1366; 1436
9 (57) −118 −266; 19 −94 −259; 48
0 129 110; 147*** 129 109; 149***
(876) −538 −2976; 1681 −788 −3529; 1439
(126) 41 −274; 328 −81 −438; 221
(2735) 1264 −6122; 8436 1208 −6017; 8620
(482) −130 −1362; 1121 −109 −1439; 1177
(102) −9 −284; 308 −98 −374; 182
(4065) 2002 −10082; 13877 4017 −8541; 16715
(5706) 3170 −13398; 19776 4936 −11808; 21750
(5997) 2631 −14520; 20118 4149 −13371; 21956
nd usual care group at baseline (age caregiver, age patient, HADS anxiety score).
care group.
Table 4 Results of the cost-effectiveness analyses for the outcomes MINI and QALYs
Analysis Outcome N Δ effects 95% CI Δ costs 95% CI# ICER Distribution cost-
effectiveness plane (%)
NE SE SW NW
ITT Unadjusted Patient-caregiver dyad QALY 192 0.006 −0.05; 0.06 2631 −14520; 201118 438299 31 27 12 30
Caregiver QALY 192 0.004 −0.04; 0.04 −538 −2976; 1681 −149984 15 43 25 17
Patient QALY 192 0.002 −0.04; 0.04 3169 −13398; 19776 1313110 31 25 11 33
Caregiver incidence of depression
and/or anxiety (MINI)*
192 −0.04 −0.20; 0.11 −538 −2976; 1681 12604 8 21 47 24
ITT Adjusted Patient-caregiver dyad QALY 192 0.04 −0.03; 0.08 4149 −13483; 21965 157534 54 30 3 13
Caregiver QALY 192 0.02 −0.005; 0.05 −788 −3551; 1453 −32254 24 71 3 2
Patient QALY 192 0.002 −0.03; 0.04 4936 −11631; 22073 2574938 35 19 9 37
Caregiver incidence of depression
and/or anxiety (MINI)*
192 0.01 −0.14; 0.17 −788 −3566; 1399 −59011 14 44 31 12
CCA Patient-caregiver dyad QALY 101 −0.005 −0.08; 0.07 3951 −17662; 25955 −807703 23 20 16 40
Caregiver QALY 119 0.02 −0.02; 0.05 −483 −2514; 1720 −24472 25 62 6 8
Patient QALY 102 −0.02 −0.07; 0.03 4373 −16422; 25402 −240247 12 12 22 54
Caregiver incidence of depression
and/or anxiety (MINI)*
106 0.08 −0.06; 0.21 −711 −2783; 1775 −9271 20 68 9 4
ITT: Intention to treat; CCA: Complete case analysis.
#95% CI obtained by bias corrected and accelerated bootstrapping.
*An effect difference >0 means that over a period of 12 months the risk of an incident depression and/or anxiety disorder was lower in the intervention group
compared to the usual care group.
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combined) were contained in the northeast quadrant of
the cost-effectiveness plane indicating some higher ef-
fects accompanied by some higher costs of the interven-
tion compared with usual care (non-significant). The
cost-effectiveness analysis for the QALY was repeated
for patients and caregivers separately, but this revealed
no significant differences either (Table 4). Based on the
CEA curves, the probability that the intervention was
considered cost-effective in comparison with usual care
was 0.33 for the outcome QALY per care dyad when the
ceiling ratio is set at €0/QALY and was 0.36 for a ceilingFigure 2 Cost-effectiveness plane for the difference in Quality Adjustratio of €30,000/QALY (Figure 3). For caregivers separ-
ately, this probability was 0.73 for a ceiling ratio of €0/
QALY and 0.85 for a ceiling ratio of €30,000/QALY. For
patients, the probability remained around 0.29 for both
ceiling ratios of €0/QALY and €30,000/QALY. For infin-
ite values of willingness to pay, the maximum probabil-
ities were 0.74, 0.95 and 0.54 for the dyads, caregivers
and patients, respectively (figures for caregivers and pa-
tients separately not shown).
Figure 4 shows the cost-effectiveness plane for the out-
come incident depression and/or anxiety, which incor-
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Figure 3 Cost-effectiveness acceptability curve for the outcome Quality Adjusted Life-Years (QALYs) per dyad. Willingness to pay
(€ per QALY gained).
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in the southern quadrants, with a somewhat higher pro-
portion in the Eastern quadrant, suggesting that the in-
tervention has lower costs accompanied by higher effects
for caregivers compared with usual care, although these
differences were statistically non-significant. The CEA
curve for this outcome shows that the maximum probabil-
ity that the intervention is cost-effective in comparison
with usual care was 0.73 at a willingness to pay of zero
euros. With increasing values for willingness to pay, the
probability that the intervention is cost-effective in com-
parison with usual care goes towards 0.57. The curveFigure 4 Cost-effectiveness plane for the incidence of depression and
that over a period of 12 months the risk of an incident depression and/or
usual care group.decreases because the cost difference for caregivers is in
favour of the intervention group (Figure not shown).
Sensitivity analyses
Two sensitivity analyses were carried out. The first in-
volved a complete case analysis using only persons with
complete follow-up data. For complete cases, the interven-
tion was not considered cost-effective in comparison with
usual care on any of the outcome measures. Effect differ-
ences for all outcomes remained small and non-significant
(Table 4). The total costs per care dyad (patient and care-
giver combined) with complete data were €64,732 (SE/or anxiety disorders in caregivers. *An effect difference >0 means
anxiety disorder was lower in the intervention group compared to the
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for the usual care group (mean adjusted cost difference
€3,951, 95% CI −17,662; 25,955). The second sensitivity
analysis contained a repetition of the ITT analysis without
adjustment for baseline imbalances between the interven-
tion and control group. Also for this analysis the interven-
tion was not considered cost-effective in comparison with
usual care on any of the outcome measures and effect and
cost differences for all outcomes remained non-significant
(Table 4). Compared to the adjusted ITT analysis, only the
MINI outcome reversed in favour of the usual care group,
but this still involved a small and non-significant difference.
Discussion
Main findings and interpretation
This study is one of the first to investigate the impact of a
dementia caregiver intervention from a societal perspective.
Total annual costs were substantial and amounted to an
average of €77,832 and €75,201 per care dyad (patient and
caregiver combined) in the intervention and usual care
group, respectively. These costs were much larger than
expected based on previous estimates of dementia care
costs [9,46]. Besides, almost half of the caregivers developed
a mental disorder [32]. Moreover, this is the first study in-
vestigating whether a structured family meetings interven-
tion for caregivers of persons with dementia is cost-effective
in comparison with usual care. The most important cost
drivers involved informal care costs and day treatment and
admission costs of hospital and long-term care facility ad-
missions of the patient. Over 12 months, we observed no
significant differences in total costs between both groups.
Based on the differences per cost category, our hypotheses
that this intervention may decrease work absenteeism and
healthcare utilization of the caregiver were not confirmed.
Only ambulatory care costs differed amongst carers in the
intervention and usual care group and were, unexpectedly,
found to be increased amongst intervention carers. It could
be possible that the intervention might have had an oppos-
ite effect by making caregivers realise they were stressed
and therefore needing to seek help, increasing their use of
ambulatory care. There were also no differences between
groups in QALYs for both patients and caregivers or on
clinical mental parameters for caregivers. Although, total
costs for caregivers in the intervention group were some-
what lower than in the usual care group and effects were
somewhat larger, cost-effectiveness planes showed that
there was substantial uncertainty. Based on these findings,
we conclude that family meetings are not cost-effective in
comparison with usual care. A possible explanation for the
non-significant findings was the minimal contrast between
the intervention and control group as a consequence of the
high level of standard care in the Netherlands. Future stud-
ies should focus on caregiving profiling based on who is
most in need of family meetings support and who wouldbenefit the most from this type of intervention. Besides, re-
search should indicate to what extent or how it is possible
to increase access, uptake and adherence.
Comparison with the existing literature
Our findings are in line with recent systematic reviews that
demonstrated little evidence for the cost-effectiveness of
non-pharmacological interventions for dementia patients
and their informal caregivers [25,26]. Since this is the first
cost-effectiveness study on family meetings, comparison of
our results with similar studies is difficult. Overall, there is
only little evidence on the cost-effectiveness of interven-
tions supporting informal caregivers. From the systematic
review of Jones et al. [25] only two randomized controlled
trials can be identified that evaluated the cost-effectiveness
of psychosocial interventions targeting informal caregivers
of dementia patients that were performed from a societal
perspective, which is considered as the most appropriate
for economic evaluations [47]. The study by Graff et al.
[27] found that community occupational therapy for de-
mentia patients, including a training programme for
caregivers in coping behaviours and supervision, was cost-
effective in comparison with usual care, and specifically
reduced costs of informal caregiving [27]. Mean costs per
patient involved €12,563 in the intervention group and
€14,311 in the usual care group after 3 months of follow-up
and were thus lower than in our study. Cost of caregivers’
healthcare utilization and medication were not reported.
The results of another economic evaluation by Wilson
et al. [48] were in line with our findings. In this cost-utility
study on a structured befriending service among 236 carers
of people with a primary progressive dementia, the inter-
vention was not found to be cost-effective [48]. Mean
QALYs per carer over 15 months were only slightly higher
(0.017) in the intervention group compared with the con-
trol groups and mean costs from a societal perspective were
£1,813 higher. The randomized trial by Roberts et al. [49]
that was included in the systematic review of Jones [25]
evaluated the effects of an individualized problem-solving
counselling intervention for caregivers and the expenditures
of their health care utilization, but costs and effects were
analysed separately [49]. Hence, this study cannot be con-
sidered a cost-effectiveness study.
Previously, the World Alzheimer Report [9] described
that in high-income countries, the direct costs of social
care (professional care in the community, and the costs
of residential and nursing home care) amounted the
most to the costs of dementia care (nearly 50%) [9]. In
our study, day treatment and admissions were also an
important cost driver, but informal care costs accounted
for the majority of the total costs (65%). This is far
higher than estimations in other cost of dementia stud-
ies. In the World Alzheimer Report [9], costs of informal
care contributed 42% to total costs worldwide [9]. This
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informal care included only tasks associated with basic
ADL and IADL, while in our study supervision time was
also incorporated. In the present study, informal care-
givers were mainly spouses living together with the per-
son with dementia and part of them reported ‘being on
duty’ 24 hours a day. Further, all patients in our sample
were living in the community at baseline, while the World
Alzheimer Report evaluation also consisted of people with
dementia living in residential or nursing home care facil-
ities. Other costing studies were more in line with our esti-
mate and reported high informal care costs. Wilson et al.
[48] found that costs of informal care contributed 85% to
the total costs on a befriending program for carers of
people with dementia [48]. In the study of Graff et al. [27]
investigating occupational therapy for dementia patients
[27], caregivers provided, on average, 11 hours a day which
is similar with our findings. These numbers emphasize the
importance of informal caregiving for people with demen-
tia living in the community.
An interesting question is why so many of our sample
developed a depressive or anxiety disorder. Caregivers
were mainly women caring for their spouse with demen-
tia. These groups of caregivers appear to be more vul-
nerable to experience adverse psychosocial and physical
health effects [3,50,51]. Further, caregivers who experi-
ence high burden and have psychological complaints
may have been more willing to participate in a trial testing
a psychosocial intervention and therefore it is possible that
recruited caregivers were at a higher risk of developing de-
pression. On the other hand, the fact that they were willing
to receive support may also have reduced their risk. The in-
cidence in the present study is far higher than found in
‘general’ elderly cohorts [52-54] and is in line with the esti-
mate of 48% reported in the review of Cuijpers et al. [3] on
depressive disorders in caregivers of dementia patients [3].
This is an alarming finding and stresses the importance of
further efforts to improve support for these caregivers. It is
already known that caregiving for dementia patients is more
stressful than caregiving for other older people, because of
the specific demands that dementia poses on the caregiver
such as being ‘on duty’ 24 hours a day and the fact that it
often lasts much longer than other caregiving, which might
explain the high vulnerability of this group [8,55].
Generalizability
Although a substantial number of caregivers refused to par-
ticipate in our study, patients and caregivers in our study
did not differ significantly from the persons who declined
participation with regard to gender, patient-caregiver rela-
tion and the service they were recruited from. Therefore,
broadly, our sample seems to be representative for the
population of caregivers and patients that receives care.
The pragmatic character of this study, with few a prioriexclusion criteria, resembling usual circumstances as much
as possible greatly enhances the generalizability of our re-
sults to the population of caregivers and patients receiving
care in daily practice.
Strengths and limitations
The major strength of this study is the detailed coverage
of all relevant costs in this specific population, including
detailed measurement of informal care. In this way, we
were able to estimate the impact of the intervention from
a societal perspective. The substantial contribution of in-
formal care costs indicates the importance of including
these costs when performing an economic evaluation in
the field of dementia. Other strengths of this study involve
the randomized design, the pragmatic approach that in-
creases the applicability of the results to daily practice, and
the relatively large sample size and long follow-up period.
A limitation of the study is the rate of incomplete data.
Complete follow-up data of costs and both the QALY and
MINI effect outcomes were available for 101/192 (53%)
caregivers and 102/192 (53%) patients. Data on costs were
self-reported by the caregiver using cost diaries, which was
rather time consuming for caregivers. Caregivers who con-
sidered withdrawal were offered a minimal assessment that
included only the main effect parameters. This minimized
dropout during the study, but decreased the completeness
of cost data. On the other hand, the rate of incomplete
data is partly due to the multi-factorial nature of data col-
lection (especially on the resource use side), and is consis-
tent with that seen in other studies. Poorer patients’ health
was significantly associated with having incomplete follow-
up data, which could have influenced the results. However,
to minimize the impact, we used multiple imputations to
impute missing data. Previous studies have shown that
simple procedures to handle missing data, like complete
case analysis, can bias the cost estimates considerably and
therefore multiple imputation is recommended to account
for missing data [56,57]. In addition, results of the com-
plete case analyses were in line with the main analyses,
which strengthen the conclusion of this study that the
intervention was not cost-effective in comparison with
usual care.
Conclusions
This family meetings intervention for caregivers of per-
sons with dementia was not cost-effective compared with
usual care. Cost-effectiveness planes showed that there
was considerable uncertainty. The limited contrast be-
tween the intervention and control group because of the
high level of standard care in the Netherlands could have
decreased the cost-effectiveness of the intervention. Fu-
ture research should focus on factors that determine
whether caregivers take up family meetings, and whether
or how it is possible to increase the uptake and adherence,
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of the intervention. Although our study did not show any
significant effects of family meetings or cost savings, the
substantial number of caregivers who developed a mental
disorder and the high informal care costs in both groups
emphasize the need to search for interventions that sup-
port caregivers of dementia patients cost-effectively across
the course of the illness.
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